
Biomarkers for Graft-Versus-Host Disease | Part 3
Biomarkers may help identify acute graft-versus-host disease patients who could be treated with alternatives to corticosteroids.
Third of four parts
Researchers are working to identify biomarkers that patients and clinicians could use to navigate GvHD treatment decisions. In a
In this segment of that interview, Paczesny discusses how a biomarker might be helpful in the treatment of acute GvHD. More specifically, she discusses how a biomarker, along with clinical evidence, might help identify lower-risk GvHD patients who could be treated with alternatives to corticosteroids. Results reported in the journal Blood showed positive results for sirolimus as a treatment for acute GVHD in a trial that compared it to prednisone as a treatment for acute GVHD.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.